News

New phase 2 findings on tralokinumab, from TRAPEDS-1, show favorable results in children 6 - 11 years with atopic dermatitis.

Piotr Witkowski, MD, PhD, discusses the CD40L inhibitor’s efficacy in improving outcomes for patients with T1D undergoing islet transplant.

MOTheR trial data suggest expanded hemodialysis offers comparable outcomes to online hemodiafiltration for dialysis patients, Patricia de Sequera, MD, PhD explains.

Justin Gregory, MD, MPH, and Steve Zortman, MPH, RN, discuss the critical need for early detection and intervention in this underrepresented population.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, discussed early clues for scarring alopecia, pipeline JAK inhibitors, and setting patient expectations.

Earlier diagnosis is imperative for chronic liver disease; Stevan Gonzalez, MD, MS, explains how PCPs and community-based screening programs can help.

During her SDPA Conference interview, Murase gave several more tips for skin management during pregnancy.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the suboptimal number of patients at risk of long-term complications due to nonadherence.

Arthur Caplan, PhD, and Dominic Sisti, PhD, revisit Jahi McMath's 5 years on a ventilator and what her case still says about how death is diagnosed.

Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

Nearly half of kidney transplant candidates never start evaluation with access barriers varying by patient background.

In this episode, Dominic Sisti and Steve Levine talk with Arthur Caplan, PhD, about how the concept of brain death was built and why it still generates controversy 50 years later.

Raj Vuppalanchi, MD, shares insights on saroglitazar, EPICS-III, and the future of personalized treatment for PBC.

Oklahoma APPs share real-world asthma and COPD biologic wins, safety surprises, and insurance hurdles as new twice-yearly options emerge.

Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.

This Q&A interview highlights Katta's views on dietary and nutritional supplements' impact on skin health as well as their long-term effects.

Tatyana Kushner, MD, joins Kim Brown, MD, and Nancy Reau, MD, to unpack bepirovirsen's phase 3 data and its implications for HBV care.

Freenome reported updated SimpleScreen CRC results showing 80.4% colorectal cancer sensitivity and 90% specificity.

Richard Shi, MD, and Adam Tanious, MD, MBA, discuss the importance of exercise, medical interventions, and smoking cessation for PAD care.

This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.

At Maui Derm Summer 2026, Hilary Baldwin, MD, used a single theoretical patient to illustrate how rosacea subtypes evolve and how treatment should follow suit.

From tighter hemodynamic definitions to a first-in-class activin signaling inhibitor, a nearly 30-year PH veteran says the field has never had more to offer patients — or more complexity to manage.

Sibeprenlimab preserved kidney function over 12 months in adults with IgA nephropathy in interim phase 3 VISIONARY trial findings.

From personalized sepsis resuscitation to the long-awaited ketamine versus etomidate verdict, a critical care NP highlights the evidence that defined the field last year.

A critical care NP and POCUS educator says point-of-care ultrasound competency is no longer optional for pulmonary and critical care APPs.

This segment of Katta's SDPA interview highlights the association between dietary changes and skin disease.

First-half 2026 hepatology highlights include FDA approvals, hepatitis B and D advances, MASH progress, and AATD gene editing.

Gregory discusses his strategies for optimizing adult male patients’ typically infrequent clinic visits to identify and forestall T1D progression.